Altreno
Real change beginsat a cellular level

Indications and Usage

Altreno® (tretinoin) Lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Important Safety Information

Altreno is for topical use only. Not for ophthalmic, oral, or intravaginal use.

Skin Irritation: Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation.

Skin Irritation

Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation. Depending upon the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of the application of Altreno, or discontinue use. Avoid application of Altreno to eczematous or sunburned skin.

Ultraviolet Light and Environmental Exposure

Minimize unprotected exposure to ultraviolet light, including sunlight and sunlamps. Warn patients with frequent sun exposure and those with inherent sensitivity to sunlight to exercise caution. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

Fish Allergies

Altreno contains soluble fish proteins. Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.

Adverse Reactions

The most common adverse reactions in clinical trials were application site dryness (4%), pain (3%), erythema (2%), irritation (1%) and exfoliation (1%).

Nursing Women

It is not known whether topical administration of tretinoin could result in sufficient systemic absorption to produce detectable concentrations in human milk. The developmental health benefits of breastfeeding should be considered along with the mother’s clinical need for Altreno and any potential adverse effects on the breastfed child from Altreno.

To report suspected adverse reactions, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

View full Prescribing Information

Skin Irritation

Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation. Depending upon the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of the application of Altreno, or discontinue use. Avoid application of Altreno to eczematous or sunburned skin.

Ultraviolet Light and
Environmental Exposure

Minimize unprotected exposure to ultraviolet light, including sunlight and sunlamps. Warn patients with frequent sun exposure and those with inherent sensitivity to sunlight to exercise caution. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

Fish Allergies

Altreno contains soluble fish proteins. Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.

Adverse Reactions

The most common adverse reactions in clinical trials were application site dryness (4%), pain (3%), erythema (2%), irritation (1%) and exfoliation (1%).

Nursing Women

It is not known whether topical administration of tretinoin could result in sufficient systemic absorption to produce detectable concentrations in human milk. The developmental health benefits of breastfeeding should be considered along with the mother’s clinical need for Altreno and any potential adverse effects on the breastfed child from Altreno.

To report suspected adverse reactions, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

View Full Prescribing Information

Indications and Usage

Altreno® (tretinoin) Lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Important Safety Information

Altreno is for topical use only. Not for ophthalmic, oral, or intravaginal use.

Skin Irritation: Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation.

Only 4% of patients reported
dry skin in clinical trials

 
 

For patients who are worried about dryness and irritation comes the only tretinoin in a hydrating lotion formulation, delivered by a unique polymeric honeycomb mesh delivery system.



01

Tretinoin

 

Tretinoin is a clinical-strength vitamin A derivative proven to treat acne and enhance both the quality and texture of skin.


02

Sodium Hyaluronate

 

Sodium hyaluronate, a form of hyaluronic acid, helps keep skin moisturized throughout the day.


03

Soluble Marine Collagen

 

Naturally hydrate with marine collagen derived from sole fish*, which moisturizes and hydrates skin.

04

Glycerin

 

Glycerin hydrates, can help protect skin from irritation and may contribute to the healing process.


*Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.

01

Tretinoin

 

Tretinoin is a clinical-strength vitamin A derivative proven to treat acne and enhance both the quality and texture of skin.

02

Sodium Hyaluronate

 

Sodium hyaluronate, a form of hyaluronic acid, helps keep skin moisturized throughout the day.

03

Soluble Marine Collagen

 

Naturally hydrate with marine collagen derived from sole fish*, which moisturizes and hydrates skin.

04

Glycerin

 

Glycerin hydrates, can help protect skin from irritation and may contribute to the healing process.

*Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.

Backed by 5 years of research,
development, and testing.
FDA-approved.

Proven inflammatory lesion reductions

Primary endpoints (over a 12-week period)

  • The mean absolute reduction in inflammatory lesion counts with Altreno Lotion was 13.1 vs 10.2 for vehicle (P<0.001)
  • 16.5% of patients experienced treatment success* vs 6.9% with vehicle (P<0.001)

Significant inflammatory
lesion reductions at week 12

Significant inflammatory lesion reductions at week 12, Trial 1, 40.4% reduction for Vihicule (n=414), 50.9% reduction for Altreno Lotion (N=406) Significant inflammatory lesion reductions at week 12, Trial 1, 40.4% reduction for Vihicule (n=414), 50.9% reduction for Altreno Lotion (N=406)
*Treatment success was defined as at least a 2-grade improvement from baseline and an Evaluator's Global Severity Score of clear (0) or almost clear (1). Results of 2 phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel- group studies comparing the efficacy and safety of Altreno lotion once daily for 12 weeks with vehicle in patients 9 years and older with moderate-to-severe acne vulgaris (baseline 20 to 40 inflammatory lesions).

Backed by 5 years of research,
development, and testing.
FDA-approved.

Proven non-inflammatory lesion reductions

Primary endpoints (over a 12-week period)

  • The mean absolute reduction in comedonal lesion counts with Altreno lotion was 17.8 vs 10.6 for vehicle (P<0.001)
  • 16.5% of patients experienced treatment success* vs 6.9% with vehicle (P<0.001)

Significant non-inflammatory
lesion reductions at week 12

Significant comedonal lesion reductions at week 12, Trial 1, 27.3% reduction for Vihicule (n=414), 47.5% reduction for Altreno Lotion (N=406) Significant comedonal lesion reductions at week 12, Trial 1, 27.3% reduction for Vihicule (n=414), 47.5% reduction for Altreno Lotion (N=406)
*Treatment success was defined as at least a 2-grade improvement from baseline and an Evaluator's Global Severity Score of clear (0) or almost clear (1). Results of 2 phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel- group studies comparing the efficacy and safety of Altreno lotion once daily for 12 weeks with vehicle in patients 9 years and older with moderate-to-severe acne vulgaris (baseline 20 to 40 inflammatory lesions).

Adverse Reactions Reported by ≥1% of Subjects Treated with Altreno and More Frequently than Vehicle

 

Altreno
(n=767)

Vehicle
(n=783)

Application-site dryness

4%

< 1%

Application-site pain*

3%

< 1%

Application-site erythema

2%

< 1%

Application-site irritation

1%

< 1%

Application-site exfoliation

1%

< 1%

*Application-site pain was defined as application-site stinging, burning, or pain.

A Vehicle of Difference

Patient survey about lotion vehicle (n=15)

80%

Skin feels more lasting moisture and hydration than what I currently use

88%

Skin feels lasting hydration

80%

Skin feels lasting moisture

80%

Skin feels more mosturized and hydrated than with what I currently use

88%

Product absorbs quickly

Altreno stimulates skin cell
turnover to treat your acne.
 
 

Physician Dispense

GET
ALTRENO

 
 
Order Now

01

Altreno Lotion 20g tube

Altreno 20g


02

Altreno Lotion 45g tube

Altreno 45g

 
Altreno

Indications and Usage

Altreno® (tretinoin) Lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Important Safety Information

Altreno is for topical use only. Not for ophthalmic, oral, or intravaginal use.

Skin Irritation: Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation.

Skin Irritation

Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation. Depending upon the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of the application of Altreno, or discontinue use. Avoid application of Altreno to eczematous or sunburned skin.

Ultraviolet Light and Environmental Exposure

Minimize unprotected exposure to ultraviolet light, including sunlight and sunlamps. Warn patients with frequent sun exposure and those with inherent sensitivity to sunlight to exercise caution. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

Fish Allergies

Altreno contains soluble fish proteins. Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.

Adverse Reactions

The most common adverse reactions in clinical trials were application site dryness (4%), pain (3%), erythema (2%), irritation (1%) and exfoliation (1%).

Nursing Women

It is not known whether topical administration of tretinoin could result in sufficient systemic absorption to produce detectable concentrations in human milk. The developmental health benefits of breastfeeding should be considered along with the mother’s clinical need for Altreno and any potential adverse effects on the breastfed child from Altreno.

To report suspected adverse reactions, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

View full Prescribing Information

 
Altreno

How Do I Get Altreno?

Altreno is a powerful Rx product, which means it requires a prescription. We can help you get in touch with a healthcare provider in two easy ways:

1. Online consultation
2. In-person visit

Get Started